 |
You can help expand this article with text translated from the corresponding article in Japanese. (January 2024) Click [show] for important translation instructions.
|topic= will aid in categorization.Content in this edit is translated from the existing Japanese Wikipedia article at [[:ja:ゼリア新薬工業]]; see its history for attribution.{{Translated|ja|ゼリア新薬工業}} to the talk page. |
 |
An editor has performed a search and found that sufficient sources exist to establish the subject's notability. Please help improve this articlebyadding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Zeria Pharmaceutical" – news · newspapers · books · scholar · JSTOR (January 2024) (Learn how and when to remove this message) |
Zeria Shinyaku Kōgyō KK (ゼリア新薬工業株式会社, Zeria Shinyaku Kōgyō Kabushiki-gaisha, Zeria Pharmaceutical Co., Ltd.) is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku[1] executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho (Zeria Pharmaceutical and Cosmetics Laboratory). In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in KumagayainSaitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance[2] as of March 2023.
Zeria holds a leading position within the gastroenterology field in Japan.[3]
In 2019, the pain reliever cream EPATEC (ketoprofen) firstly developed by Nissan Chemical Corporation was revocated authorization of Ministry of Health, Labour and Welfare around the contraindications for women in the third trimester of pregnancy.[4][5][6]
